肾肿块活检疑为嗜酸细胞瘤的手术组织病理学:系统评价与Meta分析
该系统评价与Meta分析检索1997年至2016年7月1日的MEDLINE、Embase和Cochrane数据库,纳入10个肾肿块活检系列共205例活检提示嗜酸细胞性肾肿瘤,其中46例(22.4%)接受手术。手术病理证实嗜酸细胞瘤占64.6%,嫌色细胞肾细胞癌占12.5%,其他肾细胞癌占12.5%,杂交嗜酸细胞/嫌色细胞肿瘤占6.3%,其他良性病变占4.2%。肾肿块活检诊断嗜酸细胞瘤的阳性预测值为67%(95%CI 34-94%),研究间异质性显著(I²=71.8%,P<0.01)。
要点
- 肾肿块活检提示嗜酸细胞性肾肿瘤的205例中仅46例(22.4%)接受手术。
- 活检诊断嗜酸细胞瘤的阳性预测值为67%(95%CI 34-94%),异质性I²=71.8%。
核心结论
- 肾肿块活检在自信诊断局限性肾肿块为嗜酸细胞瘤方面不可靠,四分之一手术病理为肾细胞癌。
- 患者和医生在考虑治疗策略时应知晓诊断的不确定性。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane数据库(1997年至2016年7月1日)。
- 纳入10个肾肿块活检系列(含本机构数据),共205例活检提示嗜酸细胞性肾肿瘤,其中46例(22.4%)接受手术。
- 另1项研究补充2个未被原始系列捕获的肿瘤,最终分析48个独特病灶。
主要发现
- 手术病理显示嗜酸细胞瘤占64.6%,嫌色细胞肾细胞癌占12.5%,其他肾细胞癌占12.5%。
- 杂交嗜酸细胞/嫌色细胞肿瘤占6.3%,其他良性病变占4.2%。
- 肾肿块活检诊断嗜酸细胞瘤的阳性预测值为67%(95%CI 34-94%)。
- 研究间异质性显著(I²=71.8%,P<0.01)。
- 10个系列中4个偏倚风险评为低。
关键数值与推荐
- 肾肿块活检提示嗜酸细胞性肾肿瘤后手术病理确诊嗜酸细胞瘤的阳性预测值为67%(95%CI 34-94%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间异质性显著(I²=71.8%,P<0.01)。
- 10个系列中仅4个偏倚风险评为低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To estimate the proportion of oncocytic renal neoplasms diagnosed on renal mass biopsy (RMB) confirmed on surgical pathology, a systematic review of MEDLINE, Embase, and the Cochrane databases (1997 to 1 July 2016) was conducted quantifying all cases of reported oncocytic renal neoplasms on RMB suggestive of an oncocytoma. In addition, institutional data was assessed to identify additional cases. Concordance with surgical histopathology (positive predictive value [PPV]) was evaluated for patients undergoing surgery by performing a meta-analysis. In all, 10 RMB series, including institutional data, were included in the meta-analysis with 205 RMBs identifying oncocytic renal neoplasms and 46 (22.4%) proceeding to surgery. One additional study identified two neoplasms not captured by the primary RMB series for a total of 48 unique lesions included in the analysis. Surgical pathology showed oncocytoma (64.6%), chromophobe renal cell carcinoma (RCC; 12.5%), other RCC (12.5%), hybrid oncocytic/chromophobe tumour (6.3%), and other benign lesions (4.2%). PPV of oncocytoma on RMB was 67% (95% confidence interval 34-94%) with significant heterogeneity between studies (I2 = 71.8%, P < 0.01). Risk of bias was judged to be low for four of the 10 series. Confidently diagnosing a localised renal mass as a benign lesion, such as an oncocytoma, has implications for the ultimate management strategy a patient will undergo. RMB was found to be unreliable in confidently diagnosing a localised renal mass as an oncocytoma, with one in four found to be RCC on surgical pathology. Patients and physicians should be aware of the uncertainty in diagnosis when considering management strategies.
引用
- Patel HD, Druskin SC, Rowe SP, et al. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017. PMID: 28058773. doi:10.1111/bju.13763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。